Summary
ABSTRACT Cerebral small vessel disease (SVD) encompasses a range of common processes and pathologies (arteriolosclerosis, cerebral amyloid angiopathy, small vessel atherosclerosis, small and microscopic infarcts and bleeds, enlarged perivascular spaces, and white matter disease) that we and others have shown are associated with impaired cognition and dementia (VCID). High-quality biomarkers of SVD are critically needed to advance diagnosis, prevention and treatment of small vessel VCID. The mission of the MarkVCID consortium has been to identify the most promising biomarkers of SVD, and conduc
